ANI Pharmaceuticals (NASDAQ:ANIP) CFO Sells $284,918.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 3,313 shares of the company’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $86.00, for a total transaction of $284,918.00. Following the completion of the transaction, the chief financial officer owned 177,543 shares of the company’s stock, valued at $15,268,698. This trade represents a 1.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Trading Down 1.1%

Shares of ANIP opened at $85.05 on Tuesday. ANI Pharmaceuticals, Inc. has a 1-year low of $62.60 and a 1-year high of $99.50. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06. The firm’s 50-day moving average price is $81.14 and its 200-day moving average price is $79.45. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of 21.53 and a beta of 0.43.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.28 by $0.77. The business had revenue of $237.46 million during the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. During the same period last year, the business posted $1.70 earnings per share. ANI Pharmaceuticals’s quarterly revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current year.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Pacer Advisors Inc. lifted its stake in ANI Pharmaceuticals by 6.9% during the 1st quarter. Pacer Advisors Inc. now owns 85,467 shares of the specialty pharmaceutical company’s stock valued at $6,572,000 after acquiring an additional 5,548 shares during the period. Bank of America Corp DE raised its holdings in shares of ANI Pharmaceuticals by 229.4% during the first quarter. Bank of America Corp DE now owns 150,532 shares of the specialty pharmaceutical company’s stock valued at $11,576,000 after purchasing an additional 104,828 shares during the last quarter. Janus Henderson Group PLC lifted its position in ANI Pharmaceuticals by 1,308.1% during the first quarter. Janus Henderson Group PLC now owns 109,552 shares of the specialty pharmaceutical company’s stock valued at $8,425,000 after purchasing an additional 101,772 shares during the period. California State Teachers Retirement System boosted its holdings in ANI Pharmaceuticals by 57.3% in the first quarter. California State Teachers Retirement System now owns 24,557 shares of the specialty pharmaceutical company’s stock worth $1,888,000 after purchasing an additional 8,946 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in ANI Pharmaceuticals by 1.5% in the 1st quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock worth $736,000 after purchasing an additional 143 shares during the period. 76.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on ANIP. Weiss Ratings raised ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Finally, Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $107.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.